BriaCell to present four posters at the 2026 AACR

BriaCell (BCTX) Therapeutics announces that it will present four posters at the 2026 American Association for Cancer Research, or AACR, Annual Meeting, taking place April 17-22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR. The name of the posters are: Phase II and Phase III Clinical Trials; QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 Trial; Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses; Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer; and Monitoring PD-L1 in tumor macrophage fusion cells in blood identifies high PD-L1 checkpoint inhibitor responses in metastatic breast cancer.